

# European Respiratory Society Annual Congress 2012

**Abstract Number:** 7077

**Publication Number:** P801

**Abstract Group:** 3.2. Airway Cell Biology and Immunopathology

**Keyword 1:** COPD - mechanism **Keyword 2:** Cell biology **Keyword 3:** No keyword

**Title:** Molecular mechanisms of plasminogen activator inhibitor-1 elevation in COPD sputum

Dr. Masako 417 To masakosw36ll@gmail.com MD <sup>1,2</sup>, Prof. Dr Peter J. 1134 Barnes p.j.barnes@imperial.ac.uk MD <sup>1</sup>, Dr. Kazuhiro 1135 Ito i.ito@imperial.ac.uk <sup>1</sup> and Prof. Dr Kosuke 1136 Haruki kos-h@dokkyomed.ac.jp MD <sup>2</sup>. <sup>1</sup> Airway Disease Section, National Heart and Lung Institute Imperial College, London, United Kingdom, SW3 6LY and <sup>2</sup> Department of Laboratory Medicine, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan, 343-8555 .

**Body:** [Backgrounds] Plasminogen activator inhibitor-1 (PAI-1) is an important regulator of fibrinolysis at sites of vascular injury and thrombus formation. Oxidative stress is known to involve in PAI-1 expression. We previously reported that mean PAI-1 levels in sputum of COPD was significantly higher than that of age-matched controls and significantly correlated both with sputum malondialdehyde (a oxidative stress marker) and NF-kB DNA binding activity in sputum macrophages. However, the precise mechanisms of PAI-1 elevation in COPD were not clarified. We hypothesised that HDAC2 reduction in COPD involves in PAI-1 elevation. The aim of this study was to investigate the association between HDAC2 reduction and elevated PAI-1 expression. [Methods and Results] A549 cells were transfected with SiRNA of HDAC2 to knockdown HDAC2 and followed by treatment with TGF- $\beta$ . HDAC2 knockdown (KD) significantly upregulated PAI-1 release (Wild type (WT) vs. HDAC2 KD:  $2.9 \pm 0.2$  vs.  $4.1 \pm 0.3$  ng/ml with 0.01 ng/ml TGF- $\beta$ ,  $7.4 \pm 0.4$  vs.  $8.4 \pm 0.5$  ng/ml with 0.1 ng/ml TGF- $\beta$ ). To investigate the association between NF-kB DNA binding activity and HDAC2, HDAC2 KD cells were stimulated by 10 ng/ml TNF- $\alpha$  for 2hrs, and NF-kB DNA binding activity and p65 acetylation were evaluated with TransAM NF-kB p65 Activation Assay kit and Western blot, respectively. NF-kB DNA binding activity was significantly increased in HDAC2 KD cells (activity(OD) / protein: WT vs. HDAC2 KD;  $76 \pm 4$  vs.  $98 \pm 4$ ). Acetylation of p65 also significantly upregulated in HDAC2 KD cells (acetyl-p65/p65: WT vs. HDAC2 KD;  $2.3 \pm 0.1$  vs.  $3.1 \pm 0.1$ ). [Conclusion] HDAC2 reduction in COPD seems to cause PAI-1 elevation in COPD via activation of NF-kB DNA binding by p65 acetylation.